Nurix Therapeutics Stock News

SAN FRANCISCO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc.  (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. S

Nurix Therapeutics, Inc. (NRIX) delivered earnings and revenue surprises of -26.87% and 50.67%, respectively, for the quarter ended November 2021. Do the numbers hold clues to what lies ahead for the

Related Stocks: COMP , NRIX , UPST , NEO ,

Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) have received an average rating of Buy from the eight ratings firms that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average 12 month price target among brokerages []

Nurix Therapeutics, Inc. (NASDAQ:NRIX) insider Gwenn Hansen sold 400 shares of the stock in a transaction dated Wednesday, December 1st. The stock was sold at an average price of $29.13, for a total transaction of $11,652.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Gwenn Hansen also []

Analysts expect that Nurix Therapeutics, Inc. (NASDAQ:NRIX) will report $16.24 million in sales for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Nurix Therapeutics’ earnings, with the highest sales estimate coming in at $35.46 million and the lowest estimate coming in at $8.80 million. Nurix Therapeutics posted sales of […]

Analysts expect that Nurix Therapeutics, Inc. (NASDAQ:NRIX) will post ($0.65) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Nurix Therapeutics’ earnings, with estimates ranging from ($0.79) to ($0.37). Nurix Therapeutics reported earnings per share of ($0.51) during the same quarter last year, which suggests a […]

Squarepoint Ops LLC lowered its holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 33.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,558 shares of the companys stock after selling 5,250 shares during the period. Squarepoint Ops LLCs holdings in Nurix Therapeutics []

Nurix Therapeutics is advancing a unique therapeutic approach of targeted protein modulation. The Company's current focus is on cancer treatment and small molecule immuno-oncology agents.

The clinical-stage biopharmaceutical company posted positive news regarding its lead therapy -- a BTK inhibitor that could fight certain blood-based cancers.

SVB Leerink raised the price target on Nurix Therapeutics Inc (NASDAQ: NRIX) to $64 from $50, with an Outperform rating, seeing an upside of almost 92%. Analyst Christopher Liu notes that Nurix pre

Nurix Therapeutics, Inc. (NRIX) delivered earnings and revenue surprises of 1.52% and 17.49%, respectively, for the quarter ended August 2021. Do the numbers hold clues to what lies ahead for the stoc